Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-04-10 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
国元证券股份有限公司关于安徽峆一药业股份有限公司募集资金投资项目延期的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (Guoyuan Securities) regarding the delay in the investment project funded by the company's public stock issuance. It discusses the fundraising details, project investment amounts, reasons for the delay, and the approval process by the board and supervisory committee. The document references regulatory rules related to fundraising and securities issuance, and it is focused on the status and management of the fundraising project rather than announcing new financing or capital changes. It is not a full financial report, earnings release, or management discussion. It is also not a simple announcement or certification but a formal verification opinion on the fundraising project delay. This fits best under Capital/Financing Update (CAP) as it provides an update on the use and status of raised capital and related project delays.
2024-04-10 Chinese
关于召开 2023 年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 100% confidence The document is a notice announcing the convening of the 2023 Annual General Meeting (AGM) of Anhui Xuyi Pharmaceutical Co., Ltd. It details the meeting date, voting methods (including online voting), agenda items to be discussed, and procedural information for shareholders. It references various reports and proposals to be reviewed at the AGM, such as the 2023 annual report, audit report, financial budget, and remuneration plans, but does not contain the reports themselves. The document is relatively short (4434 characters) and serves as an announcement for the AGM rather than the actual reports or voting results. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-10 Chinese
2023年度审计报告
Audit Report / Information Classification · 98% confidence The document is titled “审计报告” and contains the independent auditor’s opinion, key audit matters, and the complete audited financial statements (balance sheet, income statement, cash flows, notes). It is a standalone audit report rather than a full annual report or mere announcement. Therefore it matches the definition of an Audit Report / Information. FY 2023
2024-04-10 Chinese
国元证券股份有限公司关于安徽峆一药业股份有限公司2023年度募集资金存放与实际使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2023年度募集资金存放与实际使用情况的专项核查报告" which translates to "2023 Annual Special Verification Report on the Deposit and Actual Use of Raised Funds." It details the amount of funds raised through stock issuance, the timing of fund receipt, the use and balance of these funds, and compliance with relevant regulations. It includes detailed financial figures about the raised funds, their storage, and usage, as well as auditor verification and sponsor institution opinions. The document is a specialized audit or verification report focusing on the management and use of raised capital, not a full annual report or earnings release. It is not a simple announcement or a presentation but a detailed report on a specific financial aspect. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. The document length (5106 characters) and content confirm it is a full report, not just an announcement or certification. Therefore, the correct classification is AR with high confidence. FY 2023
2024-04-10 Chinese
非经营性资金占用及其他关联资金往来情况专项说明
Audit Report / Information Classification · 90% confidence The document is a special-purpose audit report issued by an accounting firm (容诚会计师事务所) on the company’s 2023 non-operating fund occupations and related‐party fund interactions. It is not the full annual report but a standalone audited statement and schedule prepared to comply with CSRC guidelines. This matches the definition of a standalone audit report or information (Code: AR). FY 2023
2024-04-10 Chinese
2023年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 Annual Performance Express Report" (年度业绩快报公告) and contains preliminary financial data for the year 2023, including revenue, net profit, earnings per share, and asset and equity changes. It explicitly states that the data are preliminary, unaudited, and subject to the final annual report. The document is relatively short (1774 characters) and serves as a quick earnings update rather than a full annual report. It also includes a risk warning that the final audited data will be in the formal annual report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of periodic financial results with key highlights only, not the full detailed annual report (10-K). FY 2023
2024-02-26 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.